Citius Oncology, Inc. — Form 8-K Summary
Event date: September 29, 2026. This 8-K reports the results of the company’s 2026 annual meeting of stockholders; it does not report quarterly or annual financial results.
Business context and financial information
The filing contains no revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance figures. It provides no comparison with a prior period, financial guidance, or management outlook.
Annual meeting results
- Stockholders elected Class II directors Dr. Eugene Holuka (67,835,202 votes for; 8,267,153 withheld), Robert Smith (67,883,403 for; 8,218,952 withheld), and Carol Webb (67,895,374 for; 8,206,981 withheld). Each director’s term expires at the 2029 annual meeting or when a successor is duly elected and qualified. Each nominee had 6,255,142 broker non-votes.
- Stockholders ratified Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ended September 30, 2026: 73,533,649 for, 8,809,478 against, and 14,370 abstentions; there were no broker non-votes.
Outlook, risks, and unusual items
No guidance, outlook, financial contingencies, or unusual financial items are disclosed in the provided filing text.
Investor verification points
- Confirm the director election and auditor-ratification vote counts against the filed meeting results.
- Review subsequent filings for any financial results or material developments; this 8-K is limited to annual-meeting voting matters.